Welcome to our dedicated page for Takeda Pharmaceutical news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical stock.
Takeda Pharmaceutical Company Limited reports news as a Japan-based, R&D-driven biopharmaceutical company whose American depositary shares trade under TAK. Its updates center on medicines and pipeline programs in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, including ENTYVIO, GAMMAGARD LIQUID ERC, HYQVIA, TAK-881, zasocitinib, rusfertide and oveporexton.
Recurring developments include pivotal clinical trial data, U.S. FDA regulatory actions involving new drug applications, prescription product availability, collaboration updates, and financial reports. Takeda also reports on launch preparation, generic competition affecting established products, operating-cost discipline, foreign-exchange effects, corporate transformation initiatives and governance matters tied to its global pharmaceutical business.
Takeda (TAK) will present new data from its late-stage oncology pipeline and solid tumor portfolio at the ESMO Congress 2026 in Madrid, including a late-breaking Phase 3 study of arcotatug tavatecan (TAK-921) in previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
The G-HOPE-001 registrational trial, run in Japan and China, may support a potential regulatory filing for this indication in Japan pending final results. Two presentations will feature TAK-928 in immunotherapy-resistant and first-line non-small cell lung cancer (NSCLC), alongside an update on the global Phase 3 MarsLight-11 study comparing TAK-928 to docetaxel and adding a new non-squamous NSCLC sub-trial. Takeda will also share clinical and real-world results for approved thoracic and gastrointestinal cancer medicines ALUNBRIG and FRUZAQLA.
Takeda (TAK) is committing USD 22.2 million in 2026 to four new Global CSR collaborations focused on climate‑resilient health systems in low- and middle-income countries.
The new awardees are Corus International (USD 6.4m for early warning, resilient service delivery and disaster preparedness in Nepal), Humanity & Inclusion Handicap International (USD 6.1m to strengthen inclusive, climate-resilient health systems in Honduras and Peru), KNUST (USD 5.1m to ready the pharmacy workforce for climate-responsive care in Ghana) and Terre des hommes Foundation (USD 4.6m to build climate-resilient primary healthcare in Egypt and Lebanon). These commitments increase Takeda’s total Global CSR Program contributions to USD 260.9 million across 42 collaborations worldwide, with 20 currently ongoing in 42 countries.
Takeda (TAK) received U.S. FDA Priority Review acceptance for its New Drug Application for zasocitinib (TAK-279) to treat adults with moderate-to-severe plaque psoriasis, with a PDUFA target action date in the first quarter of 2027.
The NDA is backed by pivotal global Phase 3 LATITUDE PsO 3001 and 3002 trials and the long-term LATITUDE PsO 3003 study, covering nearly 3,000 patients. At week 16, about 70% of zasocitinib-treated patients achieved clear or almost clear skin (sPGA 0/1), and 71–76% achieved PASI 75, versus 11–13% and 12% with placebo and around 30–37% with apremilast. High clearance rates were also observed at hard-to-treat sites such as scalp, nails, palms and soles. Zasocitinib was generally well tolerated, with no new safety signals identified. The EMA has accepted a marketing authorization application, and Takeda expects no significant impact on its fiscal 2027 forecast from this NDA.
Takeda (TAK) reported that the New England Journal of Medicine published results from two Phase 3 studies of oveporexton (ORZEYFUL) in adults with narcolepsy type 1 (NT1).
The FirstLight and RadiantLight trials (total n=273) showed clinically meaningful, statistically significant improvements versus placebo across wakefulness, sleepiness, cataplexy, disease severity and quality of life over 12 weeks (p<0.001). Median weekly cataplexy rates fell by 79.0%–88.8% with oveporexton compared with 27.7%–39.1% on placebo. More than 70% of treated participants reached the mildest disease severity range on the NSS‑CT, and 97% reported overall symptom improvement on the PGI‑C.
All dose groups met normative thresholds on the Maintenance of Wakefulness Test (≥20 minutes) and Epworth Sleepiness Scale (≤10). Oveporexton was generally well‑tolerated; the most common adverse events were transient insomnia, urinary urgency/frequency and excessive saliva, mostly mild to moderate. Oveporexton/ORZEYFUL is now approved for NT1 in adults in the U.S. and Japan and in adolescents ≥16 years and adults in China, with further regulatory submissions in progress.
Takeda (NYSE:TAK) received U.S. FDA approval for MIMRYLO™ (rusfertide) to treat erythrocytosis in adults with polycythemia vera (PV), a chronic blood cancer. The first-in-class, once-weekly subcutaneous hepcidin mimetic is designed to control hematocrit, the primary treatment goal in PV, and reduce reliance on phlebotomy.
Approval is based on the global Phase 3 VERIFY trial in 293 patients, where 76.9% achieved clinical response during Weeks 20–32, with benefits including hematocrit control, fewer phlebotomies and improved fatigue scores. MIMRYLO was generally well-tolerated; the most common adverse reactions were injection site reactions (56%) and anemia (16%). The label includes warnings on new or worsening thrombocytosis, injection-site reactions and embryo-fetal toxicity, with monitoring and contraception guidance. Takeda holds exclusive global development and commercialization rights and stated the approval does not change its consolidated financial forecast for FY2026.
Takeda (NYSE:TAK) announced that Japan’s Ministry of Health, Labour and Welfare approved ORZEYFUL (oveporexton) for treating adult narcolepsy type 1 (NT1), making it the first and only medicine in Japan indicated to address the underlying orexin deficiency rather than individual symptoms.
ORZEYFUL is a first‑in‑class oral orexin receptor 2 (OX2R) agonist that promotes wakefulness and reduces REM‑sleep–like phenomena, including cataplexy. Approval is supported by global Phase 3 FirstLight and RadiantLight studies, which showed statistically significant improvements across NT1 symptoms versus placebo and a generally consistent safety profile.
This MHLW decision is the third regulatory approval for ORZEYFUL worldwide, following China and the United States. In Japan, the usual adult dose is 1 mg orally twice daily, with potential up‑titration to 2 mg twice daily if well tolerated and efficacy is insufficient.
Takeda (NYSE:TAK) received U.S. FDA approval for ORZEYFUL (oveporexton), an oral orexin receptor 2 agonist indicated for treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is described as the first and only U.S. medicine to address the underlying orexin deficiency and the broad spectrum of NT1 symptoms rather than individual manifestations.
Approval is based on Phase 3 FirstLight and RadiantLight studies, which showed statistically significant improvements in excessive daytime sleepiness, cataplexy and health-related quality of life versus placebo, with a generally consistent safety profile. Common adverse reactions included insomnia, urinary frequency and urgency, and salivary hypersecretion. The Drug Enforcement Administration is reviewing its controlled substance classification, expected within 90 days, after which ORZEYFUL will be distributed via specialty pharmacy. According to Takeda, the approval is not expected to materially change its consolidated financial forecast for the fiscal year ending March 31, 2027.
Takeda (TOKYO:4502 / NYSE:TAK) reported FY2026 Q1 revenue of JPY 1,219.9 billion, up 10.2% year over year at actual exchange rates (AER), with operating profit of JPY 201.4 billion (+9.1% AER) and net profit of JPY 113.2 billion (-8.9%). Core operating profit reached JPY 358.9 billion, up 11.5% AER, while reported EPS declined to JPY 72 (-9.8%) and core EPS to JPY 154 (+1.5% AER, -11.8% CER). Operating cash flow fell to JPY 127.6 billion and adjusted free cash flow to JPY 68.6 billion.
Takeda kept its FY2026 forecast unchanged, including revenue of JPY 4,640 billion, core operating profit of JPY 1,160 billion and adjusted free cash flow of JPY 650–750 billion, and maintained an annual dividend forecast of JPY 204 per share. Pipeline momentum included the first approval of ORZEYFUL (oveporexton) in China for narcolepsy type 1, U.S. FDA Priority Review for rusfertide in polycythemia vera with a U.S. launch expected in H2 2026, and positive Phase 3 results for zasocitinib in psoriasis, with regulatory submissions planned in 2026 and a commercial launch anticipated in H1 2027.
Takeda (NYSE:TAK) reported new secondary endpoint data from two pivotal Phase 3 LATITUDE PsO 3001 and 3002 studies of its oral TYK2 inhibitor zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis. At week 16, around 70% of patients in prior topline results achieved sPGA 0/1 and PASI 75 responses emerged by week 4 and continued to rise through week 24.
According to Takeda, the new analysis shows high, consistent skin-clearance rates at hard-to-treat, high-impact sites. For scalp psoriasis, 77% and 74% of zasocitinib-treated patients achieved ssPGA 0/1 versus 7% and 13% on placebo and 42% and 30% on apremilast. For palmoplantar disease, 71% and 69% achieved hfPGA 0/1 versus 22% and 10% on placebo and 44% and 43% on apremilast. Zasocitinib also produced statistically significant NAPSI improvements versus placebo at week 16, with responses sustained to week 24 and no new safety signals; common adverse events included upper respiratory tract infection, nasopharyngitis and acne. Takeda plans to begin New Drug Application submissions for plaque psoriasis this fiscal year and is studying zasocitinib in additional immune-mediated diseases.
Takeda (NYSE:TAK) and the Government of Indonesia announced a multi-year collaboration to strengthen Indonesia’s plasma ecosystem and expand access to plasma-derived medicinal products (PDMPs). The Ministry of Health granted Takeda a plasma fractionation license, marking a key step in building local biopharmaceutical manufacturing and health resilience.
Takeda will invest up to USD 30 million over two years to pilot plasma donation centers that could later scale into a national network, following international quality standards. In parallel, Takeda will assess the feasibility of a plasma-derived therapy manufacturing facility in Indonesia. The first plasma donation center, integrated into Takeda’s BioLife network, is expected to open in 2027, with collected plasma fractionated through Takeda’s global network while prioritizing Indonesia’s domestic PDMP needs.